ACTHIB administered separately from Pentacel with no reported adverse event; Initial information received on 22-Jan-2025 regarding an unsolicited valid non-serious case received from a nurse. The case is linked to US-SA-2025SA023490. This case involves a 4 months old male patient who had HIB (PRP/T) Vaccine [ACT-HIB] administered separately from pentacel with no reported adverse event. The patient’s past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included PNEUMOCOCCAL VACCINE and DTAP WITH POLIO for Immunisation. On 22-Jan-2025, the patient received a dose of 0.5 ml of suspect HIB (PRP/T) Vaccine (Powder and solvent for solution for injection) strength, expiry date, lot number not reported via intramuscular route in the right thigh for Immunization and acthib administered separately from pentacel with no reported adverse event (wrong technique in product usage process) (latency : same day). The information on batch number and expiration date corresponding to the one at time of event occurrence was requested. Reportedly “ActHIB that was administered today was the lyophilized vaccine component of PENTACEL from yesterday or if it was the actual vaccine. Nurse caregiver wanted to know if there are possible side effects since it was given incorrectly.” This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder’s compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender’s Comments: US-SA-2025SA023490:02383817